Product Overview

Metformin 850 mg is a widely prescribed oral hypoglycemic agent used in the management of Type 2 diabetes mellitus. Manufactured by USV Pvt Ltd, this generic formulation delivers a consistent 850 mg dose of metformin in each tablet, packaged as 10 tablets per strip. The product is available in bulk pack sizes of 100, 200, or 300 tablets, providing flexibility for patients and caregivers seeking reliable supply. Designed for oral administration, the tablets are film‑coated to enhance tolerability and ensure steady absorption throughout the gastrointestinal tract. This medication is classified within the biguanide class and is recognized by major health authorities for its efficacy, safety profile, and role as a first‑line therapy in combination with lifestyle modification.

What is Metformin 850 mg

Metformin 850 mg refers to the standard therapeutic strength of the generic biguanide metformin, indicated for improving glycemic control in adults with Type 2 diabetes. The active ingredient works by decreasing hepatic glucose production, increasing peripheral insulin sensitivity, and enhancing peripheral glucose uptake. Unlike some antidiabetic agents, metformin does not stimulate insulin secretion, which reduces the risk of hypoglycemia when used as monotherapy. The 850 mg strength is commonly employed in twice‑daily dosing regimens and is bioequivalent to branded equivalents, offering the same clinical benefit at a cost‑effective price point.

Uses and Benefits

The primary use of Metformin 850 mg is to lower fasting and post‑prandial blood glucose levels in patients with Type 2 diabetes who have not achieved adequate control through diet and exercise alone. Clinical studies demonstrate that regular use can reduce HbA1c by approximately 0.5 to 1.5 percentage points, depending on baseline values and concomitant therapy. Additional benefits include modest weight neutrality or modest weight loss, improved lipid parameters such as triglycerides and LDL‑C, and a favorable cardiovascular safety record. Because metformin does not cause weight gain, it is often preferred in patients who are overweight or obese. The medication is also compatible with many other antihyperglycemic agents, allowing flexible combination regimens.

How It Works

Metformin exerts its glucose‑lowering effect through multiple mechanisms. First, it inhibits gluconeogenesis in the liver, reducing the liver’s output of glucose. Second, it enhances peripheral insulin sensitivity, enabling muscle and adipose tissue to take up glucose more efficiently. Third, it modulates intestinal absorption of glucose and alters gut microbiota, which may contribute to overall metabolic improvements. The drug is not metabolized by cytochrome enzymes; rather, it is eliminated unchanged in the urine, minimizing drug‑interaction potential. This pharmacokinetic profile supports consistent exposure and predictable therapeutic effect when taken as directed.

Dosage Guidelines

Typical initiation of Metformin 850 mg therapy involves one tablet taken with the morning meal, followed by a second tablet with the evening meal, resulting in a total daily dose of 1700 mg. The dosage may be titrated upward based on glycemic response and tolerability, with a maximum recommended daily dose of 3400 mg (divided into two 1700 mg doses). Patients with renal impairment should undergo dose adjustment; the FDA recommends a reduced dose when estimated glomerular filtration rate (eGFR) falls below 45 mL/min/1.73 m². It is essential to swallow the tablet whole with adequate water and to avoid crushing or chewing, as this may affect the protective coating and increase gastrointestinal irritation.

Side Effects

Most individuals tolerate Metformin 850 mg well, but some may experience gastrointestinal symptoms such as nausea, diarrhea, abdominal cramping, or a metallic taste. These effects are usually mild and transient, often resolving with dose titration or administration with food. Rare but serious adverse events include lactic acidosis, particularly in patients with compromised renal function, hepatic disease, or conditions predisposing to hypoxia. Signs of lactic acidosis—muscle pain, rapid breathing, unusual fatigue, abdominal discomfort—require immediate medical attention. Reporting any adverse reactions to a healthcare provider ensures timely management and safe continuation of therapy.

Warnings and Precautions

Before initiating Metformin 850 mg, clinicians should assess renal function, hepatic health, and cardiac status. The drug is contraindicated in patients with severe renal impairment (eGFR < 30 mL/min/1.73 m²), acute or chronic metabolic acidosis, or known hypersensitivity to metformin. Caution is advised in elderly patients, those undergoing radiographic contrast procedures, or individuals with conditions that may impair perfusion. Alcohol consumption should be limited, as it can increase the risk of lactic acidosis. Pregnant or breastfeeding women should consult a physician before use, as the safety profile in these populations requires individualized evaluation. For comprehensive prescribing information, refer to the FDA label or consult a qualified healthcare professional.

Frequently Asked Questions

1. Q: How long does it take to see a reduction in blood sugar levels after starting Metformin 850 mg?
   A: Most patients experience a measurable decrease in fasting glucose within 1–2 weeks of consistent dosing, with maximal glycemic effect typically observed after 4–6 weeks. Continued use, combined with diet and exercise, leads to further improvements in HbA1c over subsequent months.
2. Q: Can Metformin 850 mg be taken with other diabetes medications?
   A: Yes, metformin is frequently combined with sulfonylureas, DPP‑4 inhibitors, SGLT‑2 blockers, or insulin, provided dosing adjustments are made to avoid hypoglycemia. Always coordinate combination therapy under medical supervision.
3. Q: Is the 850 mg strength suitable for patients with kidney disease?
   A: Metformin is eliminated renally; therefore, dose reduction is recommended when eGFR is between 30–45 mL/min/1.73 m². It is contraindicated if eGFR falls below 30 mL/min/1.73 m². A healthcare provider should evaluate kidney function before prescribing.
4. Q: What should I do if I miss a dose?
   A: Take the missed tablet as soon as you remember, unless it is near the time of the next scheduled dose. In that case, skip the missed dose and resume the regular schedule. Do not double up on doses.
5. Q: Are there any dietary restrictions while on Metformin 850 mg?
   A: No specific foods must be avoided, but maintaining a balanced, low‑glycemic diet enhances glycemic control. Taking the medication with meals can reduce gastrointestinal upset.

For additional scientific details, consult resources such as the National Institutes of Health, the U.S. Food and Drug Administration, or MedlinePlus.

Related Products

• Erytop Gel (Clindamycin)
• Okamet 500 Mg (Metformin)
• Angispan TR (Nitroglycerin/Glyceryl Trinitrate)
• Angispan TR 2.5 mg (Nitroglycerin/Glyceryl Trinitrate)
• Angispan TR 6.5 mg (Nitroglycerin/Glyceryl Trinitrate)
• Glimepiride 2 mg (Generic)
• Glimepiride 1 mg (Generic)
• Glycomet-GP 0.5 Forte (Metformin/Glimepiride)
• Glycomet-GP 0.5 Tablet (Metformin/Glimepiride)
• Forxiga 5mg (Dapagliflozin)
• Glycomet-GP 1 Tablet (Metformin/Glimepiride)
• Amaryl M 1mg (Metformin/Glimepiride)